- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Moxonidine is a centrally-acting antihypertensive drug used to treat high blood pressure. It is a selective agonist of the imidazoline I1 receptor, which is found in the brain and other organs. Moxonidine works by activating the imidazoline I1 receptor, which in turn reduces sympathetic nervous system activity and lowers blood pressure. It is generally used as an adjunct to other antihypertensive drugs, such as diuretics and beta-blockers.
Moxonidine is a relatively new drug, having been approved for use in Europe in 2000 and in the United States in 2002. It is generally well-tolerated, with few side effects. Common side effects include headache, dizziness, and nausea.
The Moxonidine market is a small but growing segment of the cardiovascular drugs market. It is used to treat hypertension, a condition that affects millions of people worldwide. As such, it has the potential to become a major player in the cardiovascular drugs market.
Some companies in the Moxonidine market include Pfizer, Merck, and Novartis. Show Less Read more